Companie

Natco Pharma gets emergency nod for Baricitinib tablets to treat Covid-19

Our Bureau Hyderabad | Updated on May 03, 2021

Baricitinib in combination with Remdesivir, is used for treatment of Covid positive patients.

Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets from Central Drugs Standard Control Organization (CDSCO) in India.

Baricitinib in combination with Remdesivir, is used for treatment of Covid-19 positive patients.

Hyderabad-based Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic.

The company is ready to launch the product this week, so as to make it available to suffering patients across India, the release added.

 

Published on May 03, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

medicine
Covid-1
Natco Pharma Ltd
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.